Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

The peptide hormone, glucagon-like peptide 1 (GLP-1), has been shown to increase glucose-dependent insulin secretion, enhance insulin gene transcription, expand islet cell mass, and inhibit beta-cell apoptosis in animal models of diabetes. The aim of the present study was to evaluate whether GLP-1 could improve function and inhibit apoptosis in freshly isolated human islets. Human islets were cultured for 5 d in the presence, or absence, of GLP-1 (10 nm, added every 12 h) and studied for viability and expression of proapoptotic (caspase-3) and antiapoptotic factors (bcl-2) as well as glucose-dependent insulin production. We observed better-preserved three-dimensional islet morphology in the GLP-1-treated islets, compared with controls. Nuclear condensation, a feature of cell apoptosis, was inhibited by GLP-1. The reduction in the number of apoptotic cells in GLP-1-treated islets was particularly evident at d 3 (6.1% apoptotic nuclei in treated cultures vs. 15.5% in controls; P < 0.01) and at d 5 (8.9 vs. 18.9%; P < 0.01). The antiapoptotic effect of GLP-1 was associated with the down-regulation of active caspase-3 (P < 0.001) and the up-regulation of bcl-2 (P < 0.01). The effect of GLP-1 on the intracellular levels of bcl-2 and caspase-3 was observed at the mRNA and protein levels. Intracellular insulin content was markedly enhanced in islets cultured with GLP-1 vs. control (P < 0.001, at d 5), and there was a parallel GLP-1-dependent potentiation of glucose-dependent insulin secretion (P < 0.01 at d 3; P < 0.05 at d 5). Our findings provide evidence that GLP-1 added to freshly isolated human islets preserves morphology and function and inhibits cell apoptosis.

[1]  J. Schölmerich,et al.  Hepatocyte growth factor stimulates proliferation of pancreatic beta-cells particularly in the presence of subphysiological glucose concentrations. , 2002, Journal of molecular endocrinology.

[2]  D. Drucker.  Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. , 2003, Molecular endocrinology.

[3]  R. Perfetti,et al.  Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. , 2002, Endocrinology.

[4]  J. Holst.  Therapy of type 2 diabetes mellitus based on the actions of glucagon‐like peptide‐1 , 2002, Diabetes/metabolism research and reviews.

[5]  S. Bonner-Weir,et al.  Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. , 1999, Diabetes.

[6]  H. Edlund.  Factors controlling pancreatic cell differentiation and function , 2001, Diabetologia.

[7]  D. Drucker,et al.  Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. , 2003, Diabetes.

[8]  K. Roth,et al.  In situ immunodetection of activated caspase-3 in apoptotic neurons in the developing nervous system , 1998, Cell Death and Differentiation.

[9]  M. Prentki,et al.  Glucagon-Like Peptide 1 Induces Pancreatic β-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor , 2003 .

[10]  Jie Zhou,et al.  Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. , 1999, Diabetes.

[11]  J. Habener,et al.  Glucagon-like peptide 1 increases glucose-dependent activity of the homeoprotein IDX-1 transactivating domain in pancreatic β-cells , 2000 .

[12]  B. Friedrichsen,et al.  Regulation of-Cell Mass by Hormones and Growth Factors , 2001 .

[13]  R. Perfetti,et al.  Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5'-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. , 2003, Endocrinology.

[14]  M. Prentki,et al.  Protein Kinase Cζ Activation Mediates Glucagon-Like Peptide-1–Induced Pancreatic β-Cell Proliferation , 2001 .

[15]  C. Ricordi,et al.  Improved Human Islet Isolation Using a New Enzyme Blend, Liberase , 1997, Diabetes.

[16]  N. Greig,et al.  Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. , 1997, The Journal of clinical investigation.

[17]  C. Deacon,et al.  The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. , 2002, American journal of physiology. Endocrinology and metabolism.

[18]  C. Rhodes,et al.  IGF-I and GH post-receptor signaling mechanisms for pancreatic beta-cell replication. , 2000, Journal of molecular endocrinology.

[19]  H. Seers,et al.  OUTCOME , 1977, How to Win Your Case.

[20]  M. Itakura,et al.  Transgenic expression of FGF8 and FGF10 induces transdifferentiation of pancreatic islet cells into hepatocytes and exocrine cells. , 2002, Biochemical and biophysical research communications.

[21]  Hideki Taniguchi,et al.  Glucagon-like peptide 1 (1–37) converts intestinal epithelial cells into insulin-producing cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Michael B Wheeler,et al.  The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. , 2002, Diabetes.

[23]  A. F. Stewart,et al.  Using β-Cell Growth Factors to Enhance Human Pancreatic Islet Transplantation* , 2001 .

[24]  A. Hardikar,et al.  Functional maturation of fetal porcine beta-cells by glucagon-like peptide 1 and cholecystokinin. , 2002, Endocrinology.

[25]  B. Friedrichsen,et al.  Regulation of beta-cell mass by hormones and growth factors. , 2001, Diabetes.

[26]  S. Bonner-Weir,et al.  ENHANCED MATURATION OF PORCINE NEONATAL PANCREATIC CELL CLUSTERS WITH GROWTH FACTORS FAILS TO IMPROVE TRANSPLANTATION OUTCOME1 , 2001, Transplantation.

[27]  E. Ryan,et al.  Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. , 2000, The New England journal of medicine.

[28]  D. Harlan,et al.  Islet transplantation as a treatment for diabetes. , 2004, The New England journal of medicine.

[29]  A. F. Stewart,et al.  Transgenic overexpression of hepatocyte growth factor in the beta-cell markedly improves islet function and islet transplant outcomes in mice. , 2001, Diabetes.

[30]  J. Habener,et al.  Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. , 2002, Endocrinology.

[31]  Yazhou Li,et al.  Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis* , 2003, The Journal of Biological Chemistry.

[32]  B. Tyrberg,et al.  β-Cell Differentiation from a Human Pancreatic Cell Line in Vitro and in Vivo , 2001 .

[33]  J. Holst,et al.  Influence of glucagon-like peptide 1 on fasting glycemia in type 2 diabetic patients treated with insulin after sulfonylurea secondary failure. , 1998, Diabetes care.

[34]  J. Egan,et al.  Glucagon-like peptide-1 induces cell proliferation and pancreatic-duodenum homeobox-1 expression and increases endocrine cell mass in the pancreas of old, glucose-intolerant rats. , 2000, Endocrinology.

[35]  B. Portha,et al.  Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age. , 2001, Diabetes.

[36]  B. Portha,et al.  Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the beta-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4. , 2002, Diabetes.